2023
Assessing the Hepatic Safety of Epigallocatechin Gallate (EGCG) in Reproductive-Aged Women
Siblini H, Al-Hendy A, Segars J, González F, Taylor H, Singh B, Flaminia A, Flores V, Christman G, Huang H, Johnson J, Zhang H. Assessing the Hepatic Safety of Epigallocatechin Gallate (EGCG) in Reproductive-Aged Women. Nutrients 2023, 15: 320. PMID: 36678191, PMCID: PMC9861948, DOI: 10.3390/nu15020320.Peer-Reviewed Original ResearchConceptsReproductive-aged womenLiver function testsUterine fibroidsUnexplained infertilityClomiphene citrateSerum liver function testsEpigallocatechin gallateSigns of drugSerum folate levelsGreen tea catechinsHepatic safetyPremenopausal womenProspective cohortDaily doseLiver injuryFunction testsTreatment armsLiver toxicityClinical studiesCommon causeFolate levelsEarly safety assessmentInterim analysisNormal rangeUse of EGCG
2019
Associations Between Anti-Mullerian Hormone and Cardiometabolic Health in Reproductive Age Women Are Explained by Body Mass Index
Rios JS, Greenwood EA, Pavone MEG, Cedars MI, Legro RS, Diamond MP, Santoro N, Sun F, Robinson RD, Christman G, Zhang H, Huddleston HG. Associations Between Anti-Mullerian Hormone and Cardiometabolic Health in Reproductive Age Women Are Explained by Body Mass Index. The Journal Of Clinical Endocrinology & Metabolism 2019, 105: dgz012. PMID: 31586179, PMCID: PMC7024739, DOI: 10.1210/clinem/dgz012.Peer-Reviewed Original ResearchConceptsHomeostasis model assessment-insulin resistancePolycystic ovary syndromeAnti-Mullerian hormoneBody mass indexC-reactive proteinUnexplained infertilityWaist circumferenceOVA groupLipoprotein cholesterolMass indexRelationship of AMHModel assessment-insulin resistanceHigh-density lipoprotein cholesterolLow-density lipoprotein cholesterolSite-adjusted modelsAssessment-insulin resistanceAntral follicle countCardio-metabolic healthReproductive-aged womenMultivariable linear regression modelsReproductive-age womenClinical populationsLow-density lipoproteinCardiometabolic agingCardiometabolic indices
2018
Evaluation, validation and refinement of noninvasive diagnostic biomarkers for endometriosis (ENDOmarker): A protocol to phenotype bio-specimens for discovery and validation
Barnhart K, Giudice L, Young S, Thomas T, Diamond MP, Segars J, Youssef WA, Krawetz S, Santoro N, Eisenberg E, Zhang H, Network F. Evaluation, validation and refinement of noninvasive diagnostic biomarkers for endometriosis (ENDOmarker): A protocol to phenotype bio-specimens for discovery and validation. Contemporary Clinical Trials 2018, 68: 1-6. PMID: 29524590, PMCID: PMC5899676, DOI: 10.1016/j.cct.2018.03.002.Peer-Reviewed Original ResearchConceptsReproductive Medicine NetworkDisease-specific questionnaireReproductive-aged womenTime of surgeryEstrogen-dependent conditionStage of endometriosisExtensive clinical evaluationSeverity of diseaseNoninvasive diagnostic biomarkersAcademic medical centerPelvic painEndometrial biopsyNonsurgical diagnosisSerum cytokinesSurgical ablationGynecologic surgeryClinical evaluationClinical reasonsMedical CenterAged womenPharmacological controlEndometriosisGenomic classifierSpecific questionnaireTherapy shifts